amycretin novo nordisk - Search News

Novo Nordisk, amycretin

Novo Nordisk next-gen shot shows 22% weight loss in early results

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.

Hosted on MSN · 8h

Novo Nordisk shares pop on early-stage weight loss drug trial results

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

YAHOO!Finance · 13h

Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,

Novo Nordisk’s next-generation obesity treatment shows promise in early study

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

3hon MSN

The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week

Here are some of the major companies whose stocks moved on the week’s news.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results